# **BMC Medical Research Methodology**



**Open Access** Research article

# Reporting of Human Genome Epidemiology (HuGE) association studies: An empirical assessment

Ajay Yesupriya\*1, Evangelos Evangelou<sup>2</sup>, Fotini K Kavvoura<sup>2</sup>, Nikolaos A Patsopoulos<sup>2</sup>, Melinda Clyne<sup>1</sup>, Matthew C Walsh<sup>3</sup>, Bruce K Lin<sup>4</sup>, Wei Yu<sup>1</sup>, Marta Gwinn<sup>1</sup>, John PA Ioannidis<sup>2</sup> and Muin J Khoury<sup>1</sup>

Address: <sup>1</sup>National Office of Public Health Genomics, Coordinating Center for Health Promotion, Centers for Disease Control and Prevention, Atlanta, USA, <sup>2</sup>Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina, School of Medicine, Ioannina, Greece, 3Department of Population Health Sciences, University of Wisconsin, Madison, USA and 4Office of the Medical Director, March of Dimes Birth Defects Foundation, White Plains, USA

Email: Ajay Yesupriya\* - ayesupriya@cdc.gov; Evangelou - eevangelou@gmail.com; Fotini K Kavvoura - fainiakav@gmail.com; Nikolaos A Patsopoulos - npatsop@cc.uoi.gr; Melinda Clyne - mclyne@cdc.gov; Matthew C Walsh - walsh2@wisc.edu; Bruce K Lin - blin@marchofdimes.com; Wei Yu - wyu@cdc.gov; Marta Gwinn - mgwinn@cdc.gov; John PA Ioannidis - jioannid@cc.uoi.gr; Muin J Khoury - mkhoury@cdc.gov

\* Corresponding author

Published: 20 May 2008

BMC Medical Research Methodology 2008, 8:31 doi:10.1186/1471-2288-8-31

This article is available from: http://www.biomedcentral.com/1471-2288/8/31

© 2008 Yesupriya et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 12 September 2007 Accepted: 20 May 2008

#### **Abstract**

Background: Several thousand human genome epidemiology association studies are published every year investigating the relationship between common genetic variants and diverse phenotypes. Transparent reporting of study methods and results allows readers to better assess the validity of study findings. Here, we document reporting practices of human genome epidemiology studies.

Methods: Articles were randomly selected from a continuously updated database of human genome epidemiology association studies to be representative of genetic epidemiology literature. The main analysis evaluated 315 articles published in 2001–2003. For a comparative update, we evaluated 28 more recent articles published in 2006, focusing on issues that were poorly reported in 2001-2003.

Results: During both time periods, most studies comprised relatively small study populations and examined one or more genetic variants within a single gene. Articles were inconsistent in reporting the data needed to assess selection bias and the methods used to minimize misclassification (of the genotype, outcome, and environmental exposure) or to identify population stratification. Statistical power, the use of unrelated study participants, and the use of replicate samples were reported more often in articles published during 2006 when compared with the earlier sample.

Conclusion: We conclude that many items needed to assess error and bias in human genome epidemiology association studies are not consistently reported. Although some improvements were seen over time, reporting guidelines and online supplemental material may help enhance the transparency of this literature.

# **Background**

Human genome epidemiology (HuGE) is a rapidly emerging scientific field that examines the influence of genomic variation on human health [1-4]. Although a large and rapidly increasing number of studies have investigated the associations between genetic variants and the risks of common diseases through observational epidemiology, few significant associations have been shown to be reproducible in multiple studies [5,6]. Transparent reporting of the study populations, methods of data collection, analytic methods, and study inferences may help readers better identify issues that can affect the reproducibility of genetic association studies. Here, we conduct a detailed evaluation of reporting practices for HuGE association studies.

### **Methods**

In 2001, the Human Genome Epidemiology Network (HuGENet) established the HuGE Published Literature database (HuGE Pub Lit), a continually updated, searchable, online database of population-based, genetic epidemiology articles [7]. Relevant studies are identified weekly from NCBI PubMed [8] by a genetic epidemiologist who records the study design, genes and diseases of interest, and interacting environmental factors [7]. As of May 21, 2007, this database included a total of 27,386 articles that examined genotype-phenotype associations (both qualitative and quantitative traits) published in 2,773 journals. Further details regarding the contents of this database have been previously described [7]. This information along with the title, contributing authors, abstract, journal, date of publication, and the unique PubMed Identifier (PMID) are deposited in the HuGE Pub Lit database [7]. To select articles for this analysis, we queried the HuGE Pub Lit database for population-based studies that used observational study designs (i.e., case-control, cohort, and cross-sectional studies) to investigate genedisease associations, interactions between genetic variants (interlocus or gene-gene interactions), or gene-environment interactions. Family-based linkage studies were not collected systematically in HuGE Pub Lit and, therefore, were not included in this study. In addition, we restricted our analysis to full text articles because studies presented only as concise summaries (e.g., as letters or abstracts) could have increased the heterogeneity of our sample.

Our evaluation was designed in 2004 and data collection and analyses were conducted in 2004–2007. For the main analysis, we drew a five percent simple random sample (SRS) of articles that were returned by the query described above, published from 2001 to 2003, and curated in HuGE Pub Lit before May 30th, 2004 (n = 8,115) to yield a dataset of 406 articles. To provide an updated description of reporting practices and to assess improvements in reporting, we randomly selected (SRS) 40 articles that

were published during 2006 from articles that were returned by our database query, added to PubMed in 2006, and curated in HuGE Pub Lit before May 18, 2007 (n = 5,353). After each article was read, 91 from 2001-2003 and 12 from 2006 were excluded from the analysis for the following reasons: not written in English (2001-2003: n = 28, 2006: n = 6), population screening studies (2001-2003: n = 23, 2006: n = 0), clinical trials or pharmacogenomic studies (2001–2003: n = 16, 2006: n = 3), not full-length articles (i.e., letter or abstract) (2001-2003: n = 11, 2006: n = 0), failed to fulfill the inclusion criteria for HuGE Pub Lit [7] on closer scrutiny (2001-2003: n = 6, 2006: n = 1), family studies (2001–2003: n = 3, 2006: n = 2), studies of genetic tests (2001–2003: n = 2, 2006: n = 0), or meta-analyses (2001–2003: n = 2, 2006: n = 0).

Data were abstracted from each original publication in duplicate by two independent data extractors. All discrepancies between the independent extractors were discussed and a consensus was reached.

For the 2001-2003 articles, a standardized abstraction form was developed and piloted for 10 articles; the form was revised according to the results of this pilot study to ensure that the definitions for the collected items were clear and unambiguous. Items on this final form were designed to collect information on the reporting of study design, genotyping method, population stratification, analytical methods (including the analysis of multiple genetic variants and gene-environment interactions), and study inferences. In addition, the final form accommodated different observational study designs, multiple groups of study participants, and the consideration of more than one postulated genetic risk factor as well as additional environmental factors. Articles were coded as potentially misclassifying the disease or environmental exposure status of study participants when the article did not explicitly state that these factors were directly measured for all participants in the study population. When multiple groups of study participants were reported in a study, we recorded the sample size of the largest group for cohort and cross-sectional studies and the largest case and control groups for case-control studies. Items were collected separately for case and control groups for case-control studies and for all study participants regardless of disease status for cohort and cross-sectional studies. For the purpose of this analysis, data collected for case and control groups were combined so that statistics could be calculated for all study participants. Information (e.g., mean or median age and sex distribution) was considered as given for all study participants only if it was provided for all case and control groups. Additionally, for case-control studies, we recorded whether cases and controls were described as drawn from the same population according to one or more of the following definitions: 1) geographic region, 2) clinical population, 3) general population (i.e., ethnic group), or whether information on the choice of suitable controls was missing or incomplete.

Fourteen items were assessed in the HuGE articles published in 2006. These included the number of study participants, genes, polymorphisms, and environmental factors assessed in gene-environment interactions. In addition, we selected ten items that were applicable to all study designs and that had been reported in fewer than 50% of the articles published in 2001–2003.

The data analysis was conducted using SAS 9.13 (SAS Institute, Cary, NC). Counts and percents were calculated for the items abstracted from the articles. Comparisons of articles published in 2006 vs. those published in 2001–2003 used the Mann-Whitney U test for continuous variables and Fisher's exact test for binary variables.

# Results HuGE articles published from 2001 to 2003

The 315 articles selected for analysis were published in 194 journals and reported on the findings of 227 casecontrol, 32 cohort, and 56 cross-sectional studies. In addition to population-based studies, three articles also described family-based analyses. Data pertaining exclusively to these family-based analyses were not included in this report. As shown in Table 1, most articles (75.9 percent) reported sample sizes of fewer than 500 study participants; 9.2 percent reported sample sizes greater than or equal to 1,000 (median = 265, interquartile range (IQR) 142-471). Statistical power was reported in 12.7 percent of articles. Multiple study populations (e.g., more than one case or control group) were reported in 25.4 percent of the articles. Most of the studies provided at least some information about the origin (87.9 percent) and the enrollment criteria (97.5 percent) of the study participants. The sex distribution was provided in three-quarters of the articles, whereas the median or mean age of the study participants and a measure of the variation around this value (e.g., IQR or standard deviation) were reported for 65.4 percent and 54.6 percent, respectively. One in six articles explicitly stated that the study participants were unrelated. We estimated that 11.8 percent of studies could have misclassified the outcome of interest.

Seven percent of studies reported that the genotyping results were validated with the use of replicate samples, and an additional 9.8 percent reported that a different method of validation was used (Table 2). A blind evaluation of the genetic test to the outcome (11.1 percent) or of the outcome to the genetic test (3.8 percent) was rarely reported. Few articles reported that any potential participants had been excluded (11.8 percent) or commented on

Table 1: Reporting characteristics of the study design for 315 randomly selected HuGE articles (2001–2003)

Reporting characteristic	Count	Percent
Number of study participants		
< 100	49	15.6
100-499	190	60.3
500–999	47	14.9
>= 1000	29	9.2
Reported the available power of the study		
No	275	87.3
Yes	40	12.7
Reported that multiple study populations or case or control groups were used		
No	235	74.6
Yes	80	25.4
Provided any information on the origin of the study participants		
No.	38	12.1
Yes	277	87.9
Provided any information on the enrollment criteria for the study participants		•
No	8	2.5
Yes	307	97.5
Sex distribution reported for all study participants		
No	84	26.7
Yes	231	73.3
Mean or median age reported for all study participants	231	75.5
No No	109	34.6
Yes	206	65.4
Standard deviation or interquartile range reported for all study participants		
No	143	45.4
Yes	172	54.6
Explicitly stated the use of unrelated study participants		
No	259	82.2
Yes	56	17.8
Potential for outcome misclassification		
No	272	86.3
Unclear	6	1.9
Yes	37	11.8

the number of samples that could not be genotyped (15.6 percent).

As shown in Table 3, almost 60 percent of the articles indicated that all study participants were drawn from the same ethnic population, whereas 9.5 percent reported that the study population included more than one ethnic group. Most of these articles (76.7 percent) either stratified by or controlled for ethnicity; however, a few (23.3 percent) pooled ethnic groups together or did not provide clear information on how data from different ethnic groups were analyzed. The use of unlinked genetic markers to assess population stratification was extremely rare (0.6 percent). Among case-control studies (n = 227), two-

Table 2: Reporting characteristics of the genotyping method for 315 randomly selected HuGE articles (2001–2003)

Reporting characteristic	Count	Percent
Reported that the genotyping results were		
validated by using duplicate samples		
No	293	93.0
Yes	22	7.0
Reported that the genotyping results were validated by using a different method		
No	284	90.2
Yes	31	9.8
Reported that the evaluation of the genetic test was blind to the outcomes or phenotypes		
Blind	35	11.1
Unclear	280	88.9
Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test		
Blind	12	3.8
Unclear	303	96.2
Reported that individuals were excluded from the original group(s) of study participants		
No	278	88.2
Yes	37	11.8
Reported that several samples could not be genotyped		
No	266	84.4
Yes	49	15.6

thirds indicated that the cases and controls were drawn from the same geographic area; one in five indicated that cases and controls were drawn from the same clinical population, and one-quarter indicated that cases and controls were drawn from the same general population. More than one-third of these articles were unclear about the source populations or reported no information at all on this aspect.

Approximately one-half of the articles stated that they examined whether the study populations were in Hardy-Weinberg equilibrium; of these, 6.6 percent reported that the genotype frequencies deviated from those expected under Hardy-Weinberg equilibrium (Table 4). Summary data (e.g., genotype/allele frequencies presented in a tabular format) were reported on all genetic variants of interest for the outcomes in 87 percent of articles. Analysis using alleles (54.6 percent) was less common than analysis using genotypes (85.7 percent). When genotypes were analyzed, a considerable proportion of articles reported on specific genetic comparisons based on dominant or recessive models (20.7 percent); among these studies, 41.1 percent provided a justification for using the selected model. One in ten articles reported corrections for multiple comparisons; most (70.0 percent) used a Bonferroni correction as the method of adjustment. One article reported using both Tukey's and Scheffe's tests to control for multiple comparisons [9].

Table 3: Reporting characteristics of population stratification for 315 randomly selected HuGE articles (2001–2003)

Reporting characteristic	Count	Percent
Explicitly stated that all study participants were		
drawn from the same ethnic population		
Unclear	130	41.3
Stated	185	58.7
Analysis conducted by using different ethnic groups		
No	285	90.5
Yes	30	9.5
If different ethnic groups were included, how was ethnicity treated in the analysis ( $n = 30$ )	30	7.5
Stratified by or adjusted for ethnic groups	23	76.7
Pooled ethnic groups together	2	6.7
Unclear	5	16.6
Reported that unlinked genetic markers were used to identify population stratification	J	10.0
No	313	99.4
Yes	2	0.6
Reported that cases and controls were drawn from the same population in regards to geography ( $n = 227$ )		
No	79	34.8
Yes	148	65.2
Reported that cases and controls were drawn from the same population in regards to the clinical population ( $n = 227$ )		
No	180	79.3
Yes	47	20.7
Reported that cases and controls were drawn from the same population in regards to the general population ( $n = 227$ )		
No	167	73.6
Yes	60	26.4
Reported unclear or no information regarding the population from which cases and controls were drawn ( $n = 227$ )		
No	142	62.6
Yes	85	37.4

Overall, less than 40 percent of the articles discussed the public health, medical, or clinical implications of their findings. Less than one in six articles claimed to be the first to analyze a particular association. For the articles that did not make this claim, 8.6 percent clearly made reference to the first study on the issue. Six percent of articles clearly referenced a systematic review, and 1.9 percent referenced a non-systematic review.

Nearly two-thirds of the articles (N = 201) investigated multiple genetic variants, often in more than one gene (Table 5). These studies varied in their reporting of linkage disequilibrium (22.9 percent), haplotype analysis (21.4 percent), and gene-gene interactions (24.4 percent). When articles reported on interlocus or gene-gene interactions, slightly over half estimated the relative risk of the phenotypic outcome as an odds ratio; only 4.1 percent

Table 4: Reporting characteristics of the analytic methodology and study inferences for 315 randomly selected HuGE articles (2001–2003)

Reporting characteristic Count Percent Reported that all genetic variants were examined for Hardy-Weinberg equilibrium 164 52.1 No 151 47.9 If Hardy-Weinberg equilibrium was reported, did any polymorphism reportedly fail Hardy-Weinberg equilibrium (n = 151)Nο 141 93.4 10 Yes 6.6 Summary data reported on all genetic variants of interest for all outcomes Nο 41 13.0 Yes 274 87.0 Reported that analyses were conducted by using allele-based genetic comparisons 45.4 143 172 54.6 Reported that analyses were conducted by using genotype-based genetic comparisons 45 14.3 270 Yes 85.7 If the analyses were conducted by using genotypes, were selected comparisons or all possible comparisons assessed (n = 270)214 79.3 All possible Selected 56 20.7 Justifications given for the selection of specific genetic comparisons (n = 56)33 58.9 No 23 41.1 Adjustment for multiple comparisons used 276 87.6 No Yes 39 12.4 If an adjustment for multiple comparisons was used, type of adjustment was (n = 40, one article)used two methods) 28 70.0 Bonferroni 1 2.5 Fischer's post hoc Monte Carlo simulations 2.5 ١ Scheffe's test 2 5.0 3 7.5 Tukey's test 5 12.5 Unknown Authors discussed the public health, medical, or clinical implications of their findings 193 61.3 Yes (any mention) 122 38.7 Authors stated that this is the first study on the specific issue Nο 266 84.4 15.6 Yes Clear reference made to the first study on the specific issue (n = 266)Νo 243 91.4 23 8.6 Clear reference made to a systematic review Νo 297 94.3 Yes 18 5.7 Clear reference made to a non-systematic review 309 98.1 Nο 1.9 Yes 6

Table 5: Reporting characteristics of the analysis of multiple genetic variants for 315 randomly selected HuGE articles (2001–2003)

Reporting characteristic	Count	Percen
Number of genes analyzed		
	188	59.7
2	71	22.5
>= 3	56	17.8
Number of genetic variants analyzed	50	17.0
	114	36.2
2	85	27.0
3	56	17.8
4	21	6.6
>= 5	39	12.4
	37	12.4
Reported on linkage disequilibrium (among those		
studying 2 or more polymorphisms) (n = 201)  No	155	77. I
Yes	155 46	22.9
• • • •	40	22.9
Reported on an analysis using haplotypes (among those studying 2 or more polymorphisms) ( $n = 201$ )		
No	158	78.6
Yes	43	21.4
Reported on a interlocus or gene-gene interaction (among those studying 2 or more polymorphisms) (n = 201)		
No	152	75.6
Yes	49	24.4
If interlocus or gene-gene interactions were assessed, was risk quantified as an odds ratio or risk ratio (n = 49)		
No	22	44.9
Yes	27	55.1
If interlocus or gene-gene interactions were assessed, was risk quantified as an absolute difference (n = 49)		
No	47	95.9
Yes	2	4.1
If interlocus or gene-gene interactions were	-	•••
assessed, was risk quantified as an attributable fraction (n = 49)		
No	49	100.0
Yes	0	0.0
If interlocus or gene-gene interactions were assessed, claim was made of a statistically		
significant interaction $(n = 49)$		
No	24	49.0
Yes	25	51.0

reported an absolute difference, and none presented an attributable fraction. The remainder did not present a measure of risk. One-half of the studies that reported on interlocus or gene-gene interactions reported that at least one of these interactions was statistically significant.

Gene-environment interactions were discussed in 15.2 percent (n = 48) of the articles (Table 6). Among these articles, 70.8 percent examined one environmental factor, 20.8 percent examined two, and 8.4 percent examined

Table 6: Reporting characteristics for the analysis of interacting environmental factors for randomly selected HuGE articles (2001–2003)

Reporting characteristic	Count*	Percent
Number of environmental factors assessed in gene-environment interactions		
I	34	70.8
2	10	20.8
>= 3	4	8.4
Potential for misclassification of the environmental factors	7	0.1
No	7	14.6
Unclear	4	8.3
Yes	37	77.I
Provided a description of possible error in the measurement of the environmental factor		
No	45	93.8
Yes	3	6.2
Use of dose-depending models		
No	45	93.8
Yes	3	6.2
Reported that the evaluation of the genetic test was blind to the environmental factor		
Blind	0	0.0
Unclear	48	100.0
Reported that the evaluation of the environmental factor was blind to the genetic test		
Blind	0	0.0
Unclear	48	100.0
If gene-environmental interactions were assessed, was risk quantified as an odds ratio or risk ratio		
No	22	45.8
Yes	26	54.2
If gene-environmental interactions were assessed, was risk quantified as an absolute difference		
No	48	100.0
Yes	0	0.0
If gene-environmental interactions were assessed, was risk quantified as an attributable fraction	-	
No	48	100.0
Yes	0	0.0
Claim of a statistically significant gene- environmental interaction		
No	34	70.8
Yes	14	29.2

<sup>\*</sup> limited to the 48 studies that addressed at least 1 environmental factor

three or more. We estimated that the potential to misclassify the environmental factor was present in as many as three-fourths of the articles. Very few studies (6.2 percent) presented a description of the possible sources of error in the measurement of the environmental factor or reported the use of dose-dependent models. None of the articles indicated whether the assessment of the environmental factor was blinded to genotype or whether laboratory staff

performing the genetic tests was blind to the environmental factor. Risk was quantified as a risk or odds ratio in slightly more than one-half of these studies; however, none reported absolute differences or attributable fractions. A statistically significant gene-environment interaction was reported in 29.2 percent of the papers.

# Comparison of reporting practices in 2001-2003 with 2006

The number of study participants, genes and polymorphisms analyzed, and environmental factors examined in gene-environment interactions were similar for the two time periods (Table 7). Articles in the 2006 sample tended to use sample sizes of less than 500 (75.0 percent) and report on a single gene (75.0 percent), multiple genetic variants (64.3 percent), and no gene-environment interactions (92.9 percent).

Three of the ten items that were reported in fewer than 50 percent of the articles from 2001–2003 were reported significantly more often in the 2006 articles (Table 7). Studies published in 2006 were more likely to report the available power of the study (2001–2003: 12.7 percent; 2006: 28.6 percent; p = .03), the use of unrelated study participants (2001–2003: 17.8 percent; 2006: 35.7 percent; p = .03), and the validation of genotypic results using duplicate samples (2001–2003: 7.0 percent; 2006: 21.4 percent; p = .02). Nevertheless, every item except for Hardy-Weinberg equilibrium was reported in fewer than half of all articles in the 2006 sample.

#### **Discussion**

Many published claims of gene-disease association have not been replicated when studied in independent samples [5,6]. Suspected causes of this inconsistency include the assessment of statistical significance without accounting for the low prior probability of association, low statistical power, improper selection of participants, measurement error, confounding, and the selective reporting of results in the published literature [1,2,5,6,10-15]. Previous analyses have found that many published articles in genetic epidemiology do not provide sufficient information to evaluate these causes [16-18]. However, the results of these analyses were limited to a specific phenotypic outcome (e.g., sepsis) [16,17] or are outdated [18]. Our analysis provides an updated review of reporting on these key elements in two representative samples of HuGE articles.

Representative of the literature in this field, most of the studies in our samples were small: only about 10 percent of the studies reported sample sizes that exceeded 1,000. Several meta-analyses have found significant differences between the results of small and large genetic association studies [6,19]. Growing evidence suggests that individual genetic variants impart only a modest effect on the risk of developing complex, multifactorial diseases [20-22].

Table 7: Comparison of the reporting characteristics of HuGE articles from two time periods (2001-2003 vs. 2006)

	Published fr	om 2001–2003	Publish	ed in 2006	P-Value <sup>a</sup>
Reporting characteristic	Count	Percent	Count	Percent	
Basic descripti	ve items				
Number of study participants					
< 100	49	15.6	5	17.9	0.90
100–499	190	60.3	16	57.I	
500–999	47	14.9	4	14.3	
>= 1000	29	9.2	3	10.7	
Number of genes analyzed					
I	188	59.7	21	75.0	0.12
2	71	22.5	4	14.3	
>= 3	56	17.8	3	10.7	
Number of genetic variants analyzed					
I	114	36.2	10	35.7	0.29
2	85	27.0	4	14.3	
3	56	17.8	6	21.4	
4	21	6.6	I	3.6	
>= 5	39	12.4	7	25.0	
Number of environmental factors examined in gene-environment interactions					
I	34	70.8	I	50.0	0.26
2	10	20.8	I	50.0	
>= 3	4	8.4	0	0.0	
	less than 50% of th				
Reported the available power of the study No	less than 50% of th	87.3	20	71.4	0.03
Reported the available power of the study No Yes	less than 50% of th			71.4 28.6	0.03
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants	275 40	87.3 12.7	20 8	28.6	
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No	275 40 259	87.3 12.7 82.2	20 8	28.6 64.3	0.03
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No  Yes	275 40	87.3 12.7	20 8	28.6	
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No  Yes  Reported that genotyping results were validated using duplicate samples	275 40 259 56	87.3 12.7 82.2 17.8	20 8 18 10	28.6 64.3 35.7	0.03
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No  Yes  Reported that genotyping results were validated using duplicate samples  No	275 40 259 56 293	87.3 12.7 82.2 17.8 93.0	20 8 18 10	28.6 64.3 35.7 78.6	
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No  Yes  Reported that genotyping results were validated using duplicate samples  No  Yes	275 40 259 56	87.3 12.7 82.2 17.8	20 8 18 10	28.6 64.3 35.7	0.03
Reported the available power of the study  No Yes  Explicitly stated the use of unrelated study participants  No Yes  Reported that genotyping results were validated using duplicate samples  No Yes  Reported that genotyping results were validated using a different method	275 40 259 56 293 22	87.3 12.7 82.2 17.8 93.0 7.0	20 8 18 10 22 6	28.6 64.3 35.7 78.6 21.4	0.03
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No  Yes  Reported that genotyping results were validated using duplicate samples  No  Yes	275 40 259 56 293	87.3 12.7 82.2 17.8 93.0	20 8 18 10	28.6 64.3 35.7 78.6	0.03
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No  Yes  Reported that genotyping results were validated using duplicate samples  No  Yes  Reported that genotyping results were validated using a different method  No  Yes	275 40 259 56 293 22 284	87.3 12.7 82.2 17.8 93.0 7.0	20 8 18 10 22 6	28.6 64.3 35.7 78.6 21.4 85.7	0.03
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No  Yes  Reported that genotyping results were validated using duplicate samples  No  Yes  Reported that genotyping results were validated using a different method  No  Yes	275 40 259 56 293 22 284	87.3 12.7 82.2 17.8 93.0 7.0	20 8 18 10 22 6	28.6 64.3 35.7 78.6 21.4 85.7	0.03
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No  Yes  Reported that genotyping results were validated using duplicate samples  No  Yes  Reported that genotyping results were validated using a different method  No  Yes  Reported that genotyping results were validated using a different method  No  Yes  Reported that the evaluation of the genetic test was blind to outcomes or phenotypes	275 40 259 56 293 22 284 31	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8	20 8 18 10 22 6 24 4	28.6 64.3 35.7 78.6 21.4 85.7 14.3	0.03 0.02 0.32
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No  Yes  Reported that genotyping results were validated using duplicate samples  No  Yes  Reported that genotyping results were validated using a different method  No  Yes  Reported that genotyping results were validated using a different method  No  Yes  Reported that the evaluation of the genetic test was blind to outcomes or phenotypes  Blind  Unclear	275 40 259 56 293 22 284 31 35 280	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8	20 8 18 10 22 6 24 4	28.6 64.3 35.7 78.6 21.4 85.7 14.3	0.03 0.02 0.32
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No  Yes  Reported that genotyping results were validated using duplicate samples  No  Yes  Reported that genotyping results were validated using a different method  No  Yes  Reported that genotyping results were validated using a different method  No  Yes  Reported that the evaluation of the genetic test was blind to outcomes or phenotypes  Blind  Unclear	275 40 259 56 293 22 284 31 35 280	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8	20 8 18 10 22 6 24 4	28.6 64.3 35.7 78.6 21.4 85.7 14.3	0.03 0.02 0.32
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No  Yes  Reported that genotyping results were validated using duplicate samples  No  Yes  Reported that genotyping results were validated using a different method  No  Yes  Reported that genotyping results were validated using a different method  No  Yes  Reported that the evaluation of the genetic test was blind to outcomes or phenotypes  Blind  Unclear  Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test	275 40 259 56 293 22 284 31 35 280	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8 11.1 88.9	20 8 18 10 22 6 24 4	28.6 64.3 35.7 78.6 21.4 85.7 14.3 10.7 89.3	0.03 0.02 0.32
Reported the available power of the study  No Yes Explicitly stated the use of unrelated study participants  No Yes Reported that genotyping results were validated using duplicate samples  No Yes Reported that genotyping results were validated using a different method  No Yes Reported that genotyping results were validated using a different method  No Yes Reported that the evaluation of the genetic test was blind to outcomes or phenotypes  Blind  Unclear Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test  Blind  Unclear	275 40 259 56 293 22 284 31 35 280	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8 11.1 88.9 3.8	20 8 18 10 22 6 24 4 3 25	28.6 64.3 35.7 78.6 21.4 85.7 14.3 10.7 89.3	0.03 0.02 0.32
Reported the available power of the study  No Yes Explicitly stated the use of unrelated study participants  No Yes Reported that genotyping results were validated using duplicate samples  No Yes Reported that genotyping results were validated using a different method  No Yes Reported that genotyping results were validated using a different method  No Yes Reported that the evaluation of the genetic test was blind to outcomes or phenotypes  Blind  Unclear Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test  Blind  Unclear	275 40 259 56 293 22 284 31 35 280	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8 11.1 88.9 3.8	20 8 18 10 22 6 24 4 3 25	28.6 64.3 35.7 78.6 21.4 85.7 14.3 10.7 89.3	0.03 0.02 0.32
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No  Yes  Reported that genotyping results were validated using duplicate samples  No  Yes  Reported that genotyping results were validated using a different method  No  Yes  Reported that genotyping results were validated using a different method  No  Yes  Reported that the evaluation of the genetic test was blind to outcomes or phenotypes  Blind  Unclear  Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test  Blind  Unclear  Reported that individuals were excluded from the original group(s) of study participants	275 40 259 56 293 22 284 31 35 280	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8 11.1 88.9 3.8	20 8 18 10 22 6 24 4 3 25 2 26	28.6 64.3 35.7 78.6 21.4 85.7 14.3 10.7 89.3 7.1 92.9	0.03 0.02 0.32 0.62
Reported the available power of the study No Yes  Explicitly stated the use of unrelated study participants No Yes  Reported that genotyping results were validated using duplicate samples No Yes  Reported that genotyping results were validated using a different method No Yes  Reported that genotyping results were validated using a different method No Yes  Reported that the evaluation of the genetic test was blind to outcomes or phenotypes Blind Unclear  Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test Blind Unclear  Reported that individuals were excluded from the original group(s) of study participants No Yes	275 40 259 56 293 22 284 31 35 280 12 303	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8 11.1 88.9 3.8 96.2	20 8 18 10 22 6 24 4 3 25 2 26	28.6 64.3 35.7 78.6 21.4 85.7 14.3 10.7 89.3 7.1 92.9	0.03 0.02 0.32 0.62
Reported the available power of the study No Yes Explicitly stated the use of unrelated study participants No Yes Reported that genotyping results were validated using duplicate samples No Yes Reported that genotyping results were validated using a different method No Yes Reported that genotyping results were validated using a different method No Yes Reported that the evaluation of the genetic test was blind to outcomes or phenotypes Blind Unclear Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test Blind Unclear Reported that individuals were excluded from the original group(s) of study participants No Yes	275 40 259 56 293 22 284 31 35 280 12 303	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8 11.1 88.9 3.8 96.2	20 8 18 10 22 6 24 4 3 25 2 26	28.6 64.3 35.7 78.6 21.4 85.7 14.3 10.7 89.3 7.1 92.9	0.03 0.02 0.32 0.62
Reported the available power of the study No Yes  Explicitly stated the use of unrelated study participants No Yes  Reported that genotyping results were validated using duplicate samples No Yes  Reported that genotyping results were validated using a different method No Yes  Reported that genotyping results were validated using a different method No Yes  Reported that the evaluation of the genetic test was blind to outcomes or phenotypes Blind Unclear  Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test Blind Unclear  Reported that individuals were excluded from the original group(s) of study participants No Yes  Reported that several samples could not be genotyped	275 40 259 56 293 22 284 31 35 280 12 303 278 37	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8 11.1 88.9 3.8 96.2 88.2 11.8	20 8 18 10 22 6 24 4 3 25 2 26 26 2	28.6 64.3 35.7 78.6 21.4 85.7 14.3 10.7 89.3 7.1 92.9 92.9 7.1	0.03 0.02 0.32 0.62 0.32
Reported the available power of the study No Yes Explicitly stated the use of unrelated study participants No Yes Reported that genotyping results were validated using duplicate samples No Yes Reported that genotyping results were validated using a different method No Yes Reported that genotyping results were validated using a different method No Yes Reported that the evaluation of the genetic test was blind to outcomes or phenotypes Blind Unclear Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test Blind Unclear Reported that individuals were excluded from the original group(s) of study participants No Yes Reported that several samples could not be genotyped No Yes	275 40 259 56 293 22 284 31 35 280 12 303 278 37	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8 11.1 88.9 3.8 96.2 88.2 11.8	20 8 18 10 22 6 24 4 3 25 2 26 26 2	28.6 64.3 35.7 78.6 21.4 85.7 14.3 10.7 89.3 7.1 92.9 92.9 7.1	0.03 0.02 0.32 0.62 0.32
Reported the available power of the study No Yes Explicitly stated the use of unrelated study participants No Yes Reported that genotyping results were validated using duplicate samples No Yes Reported that genotyping results were validated using a different method No Yes Reported that genotyping results were validated using a different method No Yes Reported that the evaluation of the genetic test was blind to outcomes or phenotypes Blind Unclear Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test Blind Unclear Reported that individuals were excluded from the original group(s) of study participants No Yes Reported that several samples could not be genotyped No Yes	275 40 259 56 293 22 284 31 35 280 12 303 278 37	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8 11.1 88.9 3.8 96.2 88.2 11.8	20 8 18 10 22 6 24 4 3 25 2 26 26 2	28.6 64.3 35.7 78.6 21.4 85.7 14.3 10.7 89.3 7.1 92.9 92.9 7.1	0.03 0.02 0.32 0.62 0.32
Reported the available power of the study No Yes Explicitly stated the use of unrelated study participants No Yes Reported that genotyping results were validated using duplicate samples No Yes Reported that genotyping results were validated using a different method No Yes Reported that genotyping results were validated using a different method No Yes Reported that the evaluation of the genetic test was blind to outcomes or phenotypes Blind Unclear Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test Blind Unclear Reported that individuals were excluded from the original group(s) of study participants No Yes Reported that several samples could not be genotyped No Yes Reported that unlinked genetic markers were used to identify population stratification	275 40 259 56 293 22 284 31 35 280 12 303 278 37	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8 11.1 88.9 3.8 96.2 88.2 11.8 84.4	20 8 18 10 22 6 24 4 3 25 2 26 26 2 2 2 3 5	28.6 64.3 35.7 78.6 21.4 85.7 14.3 10.7 89.3 7.1 92.9 92.9 7.1 82.1 17.9	0.03 0.02 0.32 0.62 0.32 0.86
Reported the available power of the study  No  Yes  Explicitly stated the use of unrelated study participants  No  Yes  Reported that genotyping results were validated using duplicate samples  No  Yes  Reported that genotyping results were validated using a different method  No  Yes  Reported that genotyping results were validated using a different method  No  Yes  Reported that the evaluation of the genetic test was blind to outcomes or phenotypes  Blind  Unclear  Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test  Blind  Unclear  Reported that individuals were excluded from the original group(s) of study participants  No  Yes  Reported that several samples could not be genotyped  No  Yes  Reported that unlinked genetic markers were used to identify population stratification  No  Yes	275 40 259 56 293 22 284 31 35 280 12 303 278 37 266 49	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8 11.1 88.9 3.8 96.2 88.2 11.8 84.4 15.6	20 8 18 10 22 6 24 4 3 25 2 26 26 2 2 3 5	28.6 64.3 35.7 78.6 21.4 85.7 14.3 10.7 89.3 7.1 92.9 92.9 7.1 82.1 17.9 100.0	0.03 0.02 0.32 0.62 0.32 0.86
Reported the available power of the study No Yes  Explicitly stated the use of unrelated study participants No Yes  Reported that genotyping results were validated using duplicate samples No Yes  Reported that genotyping results were validated using a different method No Yes  Reported that genotyping results were validated using a different method No Yes  Reported that the evaluation of the genetic test was blind to outcomes or phenotypes Blind Unclear  Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test Blind Unclear  Reported that the evaluation of the outcomes or phenotypes was blind to the genetic test Blind Unclear  Reported that individuals were excluded from the original group(s) of study participants No Yes  Reported that several samples could not be genotyped No Yes  Reported that unlinked genetic markers were used to identify population stratification No	275 40 259 56 293 22 284 31 35 280 12 303 278 37 266 49	87.3 12.7 82.2 17.8 93.0 7.0 90.2 9.8 11.1 88.9 3.8 96.2 88.2 11.8 84.4 15.6	20 8 18 10 22 6 24 4 3 25 2 26 26 2 2 3 5	28.6 64.3 35.7 78.6 21.4 85.7 14.3 10.7 89.3 7.1 92.9 92.9 7.1 82.1 17.9 100.0	0.03 0.02 0.32 0.62 0.32 0.86

<sup>&</sup>lt;sup>a</sup> P-values were determined from two-sided Mann-Whitney U tests for the basic descriptive items and one sided Fisher's Exact Tests for the items that were reported in less than 50% of the 2001–2003 articles.

Thus, enrolling many thousands or even tens of thousands of individuals may be required to achieve the necessary power to identify and validate true genetic associations [13,20,23,24].

Our ability to assess the potential for selection biases was severely limited in many of the studies we examined. Although most studies provided some qualitative descriptions of the study participants (such as origin and enrollment criteria), reporting was sporadic for even simple descriptors, such as age and sex. Potentially important details, such as the number of exclusions or the number of samples that could not be genotyped, were often omitted.

Misclassification can severely limit study power and bias the results [14,23,25-27]. We determined about a tenth of studies may have misclassified their phenotypic outcomes and three-fourths of studies may have misclassified their environmental factors. A small proportion of studies reported measures such as genotyping replicate samples and blinding the research staff [27,28] to help ensure that the genetic data were not misclassified. Although the practice of detecting genotyping errors through tests of Hardy-Weinberg Equilibrium is still being debated [27,29-31], approximately half of studies reported HWE test results.

Population stratification may occur when study participants are selected from subpopulations with a different the phenotypes of and [21,30,32,33]. Although the extent to which population stratification contributes to spurious findings remains debatable [34-36], most of the articles in our sample provided descriptions for the ethnic origin of the study participants, and almost all case-control studies indicated that the cases and controls were drawn from the same population. A few studies reported the use of unlinked markers to provide evidence that population stratification was not an issue in the analysis. Genome-wide association studies provide considerable genetic data to examine and correct for population stratification (e.g. by principal component analysis) [37-39].

As a result of the selective reporting of significant results from multiple analyses and publication bias, the extent of type I error in the published literature may be great [11,14,21,23,26,28,30,40,41]. Although most studies reported results for only a few polymorphisms and environmental factors, it is difficult to determine the number actually tested; only a minority of articles reported using corrections for multiple comparisons, even for the reported associations. Reporting justifications for specific genetic comparisons could suggest that studies were founded on an a priori hypothesis and were not the result of selective reporting. However, less than one-half of the studies that assessed dominant or recessive genetic models provided justifications for the use of these specific comparisons and not others. Among articles that described gene-gene or gene-environment interactions, a substantial proportion reported statistically significant results. However, many of these may be spurious, given the limited power of most studies to identify true associations, let alone interaction effects [20,32]. The high frequency of "positive" results in our study sample could reflect a combination of multiple testing, selective reporting, and publication bias [14].

The use of common reporting standards could increase the transparency of research methodology, thus helping to identify selective reporting and sources of bias and confounding while allowing for a more complete synthesis of data across consortia or in meta-analyses [1,10,42]. The results of our study were presented at a HuGENet sponsored workshop, Strengthening the Reporting of Genetic Associations (STREGA) [43]. The workshop concluded with an agreement to develop an extension of the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) statement [44] to address some of the specific challenges (e.g., generation of genetic data, population stratification, haplotype inference, HWE, and multiple testing) posed by reporting results of genetic epidemiology studies. STREGA is currently finalized for publication, as of writing this article.

By publishing supplementary information online, journals increasingly provide authors the opportunity to present their study methods and results in greater detail than is permitted in print [45,46]. Recently, an increase in such supplements–often used to report additional methods, tables, and figures–was documented for a number of high impact journals [45]. However, authors and journals need to ensure that this information remains available to readers and is not lost in broken links [46].

#### Conclusion

In summary, our results provide evidence that many details needed to assess the validity of study findings are not consistently reported in human genome epidemiology studies, though some improvement has been seen recently. The use of standard reporting guidelines and online supplements could help readers to better judge the scientific evidence. As large-scale genotyping platforms are rapidly introduced in human genome epidemiology, the importance of transparent reporting of the background, epidemiological methods, and population characteristics cannot be understated given the challenge of assessing, interpreting, and discussing ever-greater amounts of data.

### **Competing interests**

The authors declare that they have no competing interests.

# **Authors' contributions**

AY assisted in data collection, performed the analysis, and drafted the manuscript. EE, FKK, and NAP assisted in data collection and the revision of the manuscript. MC identified and indexed relevant articles for the HuGE Published Literature database. MCW and BKL created the standardized abstraction form and assisted in the sampling process

and data collection. WY curates the HuGE Published Literature and assisted in the sampling process. MG, JPAI, and MJK designed the study, oversaw the project, and revised the manuscript. All authors read and approved the final manuscript.

#### Note

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

# **Acknowledgements**

None.

#### References

- Little J, Khoury MJ, Bradley L, Clyne M, Gwinn M, Lin B, Lindegren ML, Yoon P: The human genome project is complete. How do we develop a handle for the pump? Am J Epidemiol 2003, 157(8):667-673.
- Khoury MJ, Millikan R, Little J, Gwinn M: The emergence of epidemiology in the genomics age. Int J Epidemiol 2004, 33(5):936-944.
- Khoury MJ, Dorman JS: The Human Genome Epidemiology Network. Am J Epidemiol 1998, 148(1):1-3.
- Khoury MJ: Human genome epidemiology: translating advances in human genetics into population-based data for medicine and public health. Genet Med 1999, 1(3):71-73.
- Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K: A comprehensive review of genetic association studies. Genet Med 2002, 4(2):45-61.
- loannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG: Genetic associations in large versus small studies: an empirical assessment. Lancet 2003, 361(9357):567-571.
- Lin BK, Clyne M, Walsh M, Gomez Ö, Yu W, Gwinn M, Khoury MJ: Tracking the Epidemiology of Human Genes in the Literature: The HuGE Published Literature Database. Am J Epidemiol 2006, 164(1):1-4.
- B. NCBI PubMed [http://www.ncbi.nlm.nih.gov/entrez/guery.fcgi?DB=pubmed]
- Xia Y, Gueguen R, Vincent-Viry M, Siest G, Visvikis S: Effect of six candidate genes on early aging in a French population. Aging Clin Exp Res 2003, 15(2):111-116.
- 10. Ioannidis JP, Gwinn M, Little J, Higgins JP, Bernstein JL, Boffetta P, Bondy M, Bray MS, Brenchley PE, Buffler PA, Casas JP, Chokkalingam A, Danesh J, Smith GD, Dolan S, Duncan R, Gruis NA, Hartge P, Hashibe M, Hunter DJ, Jarvelin MR, Malmer B, Maraganore DM, Newton-Bishop JA, O'Brien TR, Petersen G, Riboli E, Salanti G, Seminar D, Smeeth L, Taioli E, Timpson N, Uitterlinden AG, Vineis P, Wareham N, Winn DM, Zimmern R, Khoury MJ: A road map for efficient and reliable human genome epidemiology. Nat Genet 2006, 38(1):3-5.
- loannidis P: Genetic associations: false or true? Trends Mol Med 2003, 9(4):135-138.
- 12. Ioannidis JP: Contradicted and initially stronger effects in highly cited clinical research. Jama 2005, 294(2):218-228.
- Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN: Metaanalysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003, 33(2):177-182.
- Colhoun HM, McKeigue PM, Davey Smith G: Problems of reporting genetic associations with complex outcomes. Lancet 2003, 361(9360):865-872.
- Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N: Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004, 96(6):434-442.
- Peters DL, Barber RC, Flood EM, Garner HR, O'Keefe GE: Methodologic quality and genotyping reproducibility in studies of tumor necrosis factor -308 G-->A single nucleotide polymorphism and bacterial sepsis: implications for studies of complex traits. Crit Care Med 2003, 31(6):1691-1696.

- Clark MF, Baudouin SV: A systematic review of the quality of genetic association studies in human sepsis. Intensive Care Med 2006. 32(11):1706-1712.
- Bogardus ST Jr., Concato J, Feinstein AR: Clinical epidemiological quality in molecular genetic research: the need for methodological standards. *Jama* 1999, 281(20):1919-1926.
   Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG:
- Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG: Replication validity of genetic association studies. Nat Genet 2001, 29(3):306-309.
- loannidis JP, Trikalinos TA, Khoury MJ: Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol 2006, 164(7):609-614.
- Hirschhorn JN, Altshuler D: Once and again-issues surrounding replication in genetic association studies. J Clin Endocrinol Metab 2002, 87(10):4438-4441.
- Zondervan KT, Cardon LR: The complex interplay among factors that influence allelic association. Nat Rev Genet 2004, 5(2):89-100.
- Newton-Cheh C, Hirschhorn JN: Genetic association studies of complex traits: design and analysis issues. Mutat Res 2005, 573(1-2):54-69.
- Davey Smith G, Ebrahim S, Lewis S, Hansell AL, Palmer LJ, Burton PR: Genetic epidemiology and public health: hope, hype, and future prospects. Lancet 2005, 366(9495):1484-1498.
- Hattersley AT, McCarthy MI: What makes a good genetic association study? Lancet 2005, 366(9493):1315-1323.
- Page GP, George V, Go RC, Page PZ, Allison DB: "Are we there yet?": Deciding when one has demonstrated specific genetic causation in complex diseases and quantitative traits. Am J Hum Genet 2003, 73(4):711-719.
- Pompanon F, Bonin A, Bellemain E, Taberlet P: Genotyping errors: causes, consequences and solutions. Nat Rev Genet 2005, 6(11):847-859.
- Romero R, Kuivaniemi H, Tromp G, Olson J: The design, execution, and interpretation of genetic association studies to decipher complex diseases. Am J Obstet Gynecol 2002, 187(5):1299-1312.
- Trikalinos TA, Salanti G, Khoury MJ, Ioannidis JP: Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol 2006, 163(4):300-309
- Balding DJ: A tutorial on statistical methods for population association studies. Nat Rev Genet 2006, 7(10):781-791.
- Leal SM: Detection of genotyping errors and pseudo-SNPs via deviations from Hardy-Weinberg equilibrium. Genet Epidemiol 2005, 29(3):204-214.
- Cordell HJ, Clayton DG: Genetic association studies. Lancet 2005, 366(9491):1121-1131.
- Cardon LR, Palmer LJ: Population stratification and spurious allelic association. Lancet 2003, 361(9357):598-604.
- Freedman ML, Reich D, Penney KL, McDonald GJ, Mignault AA, Patterson N, Gabriel SB, Topol EJ, Smoller JW, Pato CN, Pato MT, Petryshen TL, Kolonel LN, Lander ES, Sklar P, Henderson B, Hirschhorn JN, Altshuler D: Assessing the impact of population stratification on genetic association studies. Nat Genet 2004, 36(4):388-393.
- Marchini J, Cardon LR, Phillips MS, Donnelly P: The effects of human population structure on large genetic association studies. Nat Genet 2004, 36(5):512-517.
- Wacholder S, Rothman N, Caporaso N: Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2000, 92(14):1151-1158.
- Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D: Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006, 38(8):904-909.
- Gibbs JR, Singleton A: Application of genome-wide single nucleotide polymorphism typing: simple association and beyond. PLoS Genet 2006, 2(10):e150.
- Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447(7145):661-678.
- Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG: Empirical evidence for selective reporting of outcomes in

- randomized trials: comparison of protocols to published articles. Jama 2004, 291 (20):2457-2465.
- 41. Khoury MJ: The case for a global human genome epidemiology initiative. Nat Genet 2004, 36(10):1027-1028.
- 42. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, Hanson J, Khoury M, Lau J, O'Brien TR, Rothman N, Stroup D, Taioli E, Thomas D, Vainio H, Wacholder S, Weinberg C: Reporting, appraising, and integrating data on genotype prevalence and genedisease associations. Am J Epidemiol 2002, 156(4):300-310.
- 43. STrengthening the REporting of Genetic Associations (STREGA): an international HuGE workshop held in Ottawa, Canada, June 15-16, 2006 [http://www.cdc.gov/genom ics/hugenet/strega.htm]
- 44. STROBE statement: Checklist of essential items Version 3
- [http://www.strobe-statement.org/]
  Schriger DL, Ouk S, Altman DG: The use of the World Wide
  Web by medical journals in 2003 and 2005: an observational study. Pediatrics 2007, 119(1):e53-60.
- 46. Evangelou E, Trikalinos TA, loannidis JP: Unavailability of online supplementary scientific information from articles published in major journals. Faseb J 2005, 19(14):1943-1944.

# **Pre-publication history**

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2288/8/31/prepub

Publish with **Bio Med Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- · yours you keep the copyright

Submit your manuscript here: http://www.biomedcentral.com/info/publishing\_adv.asp

